Head-To-Head Comparison: Editas Medicine (NASDAQ:EDIT) versus Nutra Pharma (OTCMKTS:NPHC)

Editas Medicine (NASDAQ:EDIT) and Nutra Pharma (OTCMKTS:NPHC) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, dividends and profitability.

Valuation & Earnings

This table compares Editas Medicine and Nutra Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Editas Medicine	$40.52 million	5.96	-$160.06 million	($1.23)	-2.00
Nutra Pharma	$390,000.00	5.51	-$1.29 million	N/A	N/A

Nutra Pharma has lower revenue, but higher earnings than Editas Medicine.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Editas Medicine and Nutra Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Editas Medicine	1	1	5	0	2.57
Nutra Pharma	0	0	0	0	0.00

Editas Medicine presently has a consensus target price of $5.40, suggesting a potential upside of 119.07%. Given Editas Medicine’s stronger consensus rating and higher probable upside, analysts plainly believe Editas Medicine is more favorable than Nutra Pharma.

Profitability

This table compares Editas Medicine and Nutra Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Editas Medicine	-281.59%	-677.39%	-58.25%
Nutra Pharma	-429.26%	N/A	-106.42%

Volatility and Risk

Editas Medicine has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500. Comparatively, Nutra Pharma has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500.

Insider & Institutional Ownership

71.9% of Editas Medicine shares are held by institutional investors. 3.1% of Editas Medicine shares are held by insiders. Comparatively, 61.5% of Nutra Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Editas Medicine beats Nutra Pharma on 9 of the 12 factors compared between the two stocks.

About Editas Medicine

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

About Nutra Pharma

Nutra Pharma Corp., a biopharmaceutical company, acquires, licenses, and commercializes pharmaceutical products and technologies, and homeopathic and ethical drugs for the management of pain, neurological disorders, cancer, and autoimmune and infectious diseases primarily in the United States. The company offers Nyloxin and Nyloxin Extra Strength products, which are used as an oral spray for treating lower back pain, migraines, neck aches, shoulder pain, cramps, and neuropathic pain, as well as a topical gel for treating joint pain, and pain associated with arthritis and repetitive stress; Pet Pain-Away, a homeopathic, nonnarcotic, nonaddictive, and overthecounter pain reliever to treat chronic pain in companion animals; Luxury Feet, an over-the-counter pain reliever and antiinflammatory product to treat pain or discomfort due to high heels and stilettos; Nyloxin Military Strength for treating pain to the United States Military and Veteran's Administration; and Equine Pain-Away, an over-the-counter topical pain reliever to relieve pain in horses. It is also involved in developing RPI-78M to treat neurological diseases and autoimmune diseases, including multiple sclerosis, adrenomyeloneuropathy, amyotrophic lateral sclerosis, rheumatoid arthritis, and myasthenia gravis; RPI-MN to treat viral diseases comprising human immunodeficiency virus/AIDS and herpes, as well as for general anti-viral applications; RPI-78 for pain and arthritis; and RPI-70 for pain. The company was incorporated in 2000 and is based in Plantation, Florida.